A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and Gastric Cardia
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 63
- 试验地点
- 1
- 主要终点
- Recurrence Free Survival (RFS) compared to historical averages
研究概览
简要总结
This phase II trial studies how well oxaliplatin, leucovorin calcium, and fluorouracil followed by surgery and response based concurrent chemotherapy and radiation therapy works in treating patients with cancer of the esophagus, gastroesophageal junction, or gastric cardia. Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill tumor cells. Giving chemotherapy followed by surgery and response based chemotherapy and radiation therapy may kill more tumor cells.
详细描述
PRIMARY OBJECTIVES:
I. To assess the ability of response adapted adjuvant chemoradiotherapy to improve the 1 year recurrence free survival (RFS) compared to historical data in patients with > 50% remaining viable tumor after induction chemotherapy.
SECONDARY OBJECTIVES:
I. To determine the rates of symptomatic, endoscopic, and pathologic response to induction chemotherapy.
II. To determine the rate of R0 resection after induction chemotherapy. III. To establish the toxicity profile of this tri-modality regimen. IV. To assess the recurrence free survival (RFS) and overall survival (OS) of this trimodality therapy regimen for the entire cohort and in patients who do and do not achieve a pathologic response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a histologic diagnosis of adenocarcinoma of the esophagus, GEJ, or GC based on biopsy material or adequate cytologic exam; tumors of the GC are defined as originating within 5 cm of the GEJ
- •Patients must be clinically staged according to the 7th edition (2010) of the American Joint Committee on Cancer (AJCC) staging system and must have either clinical T3-4a, or ≥ N1 disease; staging should include upper endoscopy with endoscopic ultrasound and a fludeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) scan (with diagnostic CT abdomen/pelvis preferred)
- •Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •Absolute neutrophil count ≥ 1,500/ul
- •Platelet count ≥100,000/ul
- •Serum creatinine (Scr) ≤ 1.5mg/dl; if the Scr > 1.5, patients may still be eligible if the calculated glomerular filtration rate (GFR) (Cockroft-Gault) is ≥ 40ml/minute
- •Serum total bilirubin ≤ 1.5X the institutional upper limit of normal (ULN)
- •Alkaline phosphatase ≤ 3X the institutional ULN
- •Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3X the institutional ULN
- •Patients with Gilbert's syndrome are eligible provided the total bilirubin is ≤ 3 and the remainder of the liver function tests (ALT, AST, alkaline phosphatase [ALK Phos]) are within the institutional normal range
- •Patients must have a forced expiratory volume in one second (FEV-1) and diffusing capacity of the lung for carbon monoxide (DLCO) > 50% predicted
- •Patients or their legal representatives must be able to read, understand, provide and sign informed consent to participate in the trial
- •Patients of childbearing potential must agree to use an effective form of contraception during this study and for 90 days following the last dose of chemotherapy; an effective form of contraception is an oral contraceptive or a double barrier method
排除标准
- •Patients with any other diagnosis except for adenocarcinoma (squamous cell carcinoma, small cell carcinoma, mixed adenosquamous, lymphoma, sarcoma, etc.) will be ineligible
- •Patients with evidence of clinical T4b (unresectable) or M1 (distant metastasis) according to the AJCC 2010 staging system will be ineligible
- •No prior chemotherapy, radiation therapy, or surgery for this malignancy will be allowed; prior endoscopic procedures for superficial disease (endoscopic mucosal resection, cryotherapy, photodynamic therapy, etc.) will not exclude a patient; prior dilatation is also allowed
- •Patients with another active malignancy will not be eligible except for:
- •Resected basal cell carcinoma and squamous cell carcinoma of the skin, cervical or prostatic intraepithelial neoplasia, and ductal or lobular carcinoma in situ of the breast
- •Patients with localized prostate cancer who have received curative intent therapy are also eligible provided:
- •Surgically treated patients have an undetectable prostate specific antigen (PSA)
- •Patients treated with brachytherapy have a PSA within the institutional normal range
- •Patients who have received pelvic external beam radiotherapy are not eligible
- •Patients with a clinically apparent active infection will not be eligible (please note, an isolated elevation in the white blood cell count, by itself, does not constitute evidence of an infection)
- •Patients with known hypersensitivity to any component of the chemotherapy regimen will not be eligible
- •Patients with a baseline peripheral neuropathy ≥ grade 2 will not be eligible
- •Patients who are receiving any other concurrent investigational therapy, or who have received investigational therapy within 30 days of the first scheduled day of protocol treatment (investigational therapy as defined as treatment for which there is currently no regulatory authority approved indication) will not be eligible
- •Patients who are pregnant or lactating will not be eligible; pregnant patients are ineligible
- •Patients with angina, a cardiac ejection fraction < 50%, or ischemic heart disease are not eligible
- •Patients with any other medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with the patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results, will not be eligible
- •Patients with any history of solid organ or bone marrow transplant will not be eligible
- •Patients with a known history of infection with hepatitis B or hepatitis C virus (active, previously treated, or both) will not be eligible due to the increased risk of hepatotoxicity and viral reactivation associated with systemic chemotherapy
- •Patients with known infection with human immunodeficiency virus (HIV) will not be eligible
研究组 & 干预措施
Positive Pathologic Response
Patients with ≤50% viable tumor cells remaining in the surgical specimen will receive postoperative chemo-radiotherapy with the mFOLFOX6 regimen
干预措施: oxaliplatin (Drug)
Positive Pathologic Response
Patients with ≤50% viable tumor cells remaining in the surgical specimen will receive postoperative chemo-radiotherapy with the mFOLFOX6 regimen
干预措施: leucovorin calcium (Drug)
Positive Pathologic Response
Patients with ≤50% viable tumor cells remaining in the surgical specimen will receive postoperative chemo-radiotherapy with the mFOLFOX6 regimen
干预措施: fluorouracil (Drug)
Positive Pathologic Response
Patients with ≤50% viable tumor cells remaining in the surgical specimen will receive postoperative chemo-radiotherapy with the mFOLFOX6 regimen
干预措施: therapeutic conventional surgery (Procedure)
Positive Pathologic Response
Patients with ≤50% viable tumor cells remaining in the surgical specimen will receive postoperative chemo-radiotherapy with the mFOLFOX6 regimen
干预措施: radiation therapy (Radiation)
Negative Pathologic Response
Patients with >50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
干预措施: oxaliplatin (Drug)
Negative Pathologic Response
Patients with >50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
干预措施: leucovorin calcium (Drug)
Negative Pathologic Response
Patients with >50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
干预措施: fluorouracil (Drug)
Negative Pathologic Response
Patients with >50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
干预措施: therapeutic conventional surgery (Procedure)
Negative Pathologic Response
Patients with >50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
干预措施: radiation therapy (Radiation)
Negative Pathologic Response
Patients with >50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
干预措施: carboplatin (Drug)
Negative Pathologic Response
Patients with >50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
干预措施: paclitaxel (Drug)
结局指标
主要结局
Recurrence Free Survival (RFS) compared to historical averages
时间窗: 1 year
Compare the number of study patients who achieved RFS with \>50% remaining viable tumor after response adapted adjuvant chemoradiotherapy to historical data among patients with \>50% viable tumor after induction chemotherapy. A once sided test (p\<=0.05) will be used to describe significance of change.
次要结局
- Pathologic response(Up to 5 years)
- Endoscopic response(Up to 5 years)
- Symptomatic response(Up to 5 years)
- Complete resection (R0) rate(Up to 5 years)
- OS(Time from start of treatment until death due to any cause, assessed up to 5 years)
- Rate of Distant Metastatic Control (DMC)(Up to 5 years)
- Loco-regional control (LRC)(Up to 5 years)
- Incidence of toxicity(Up to 5 years)
- RFS within study patients(Time from start of treatment until first recurrence or death from any cause, assessed up to 5 years)